Evidence map›Paper›PMID 42338594›Full record

ArticleFrontiers in immunology2026

Evaluation of a strain Long human respiratory syncytial virus with

Ri-Gan Shu, Jie Jun, Yun-Xuan Zheng, Dan-Ning Yue, Hao Hu, Hua-Wei Xu, Xiao-Lei Zhao, Hong-Ru Wang, Xi-Man Liu, Yi-Peng Zhang and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ri-Gan Shu *College of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing, China.
Jie Jun *College of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing, China.
Yun-Xuan ZhengCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing, China.
Dan-Ning YueCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing, China.
Hao HuCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing, China.
Hua-Wei XuCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing, China.
Xiao-Lei ZhaoCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing, China.
Hong-Ru WangCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing, China.
Xi-Man LiuCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing, China.
Yi-Peng ZhangCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing, China.
He WangCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing, China.
Jie-Mei YuCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing, China.
Yan-Peng ZhengCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing, China.
Xiang-Lei PengCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing, China.
Yuan-Hui FuCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing, China.
Jin-Sheng HeCollege of Life Sciences and Bioengineering, Beijing Jiaotong University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Human respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract illness (LRTI) worldwide, particularly in infants, the elderly and immunocompromised individuals. Despite this substantial disease burden, no licensed pediatric vaccines are currently available for infants aged ≥ 6 months, highlighting an urgent need for effective immunization strategies. Methods: Live-attenuated vaccines (LAVs) were developed and characterized based on RSV subgroup A strain Long ( Results: In HEp-2 and Vero cells, the recombinant strains RLΔM2-2 and RLΔM2-2112 displayed reduced replication capability compared with the parental Conclusion: These results support the application of

Indexed as

Gene DeletionRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesViral ProteinsAdministration, IntranasalAnimalsAntibodies, NeutralizingAntibodies, ViralChlorocebus aethiopsFemaleHumansLungMiceMice, Inbred BALB CVaccinationAntibodies, NeutralizingAntibodies, ViralM2-2 protein, respiratory syncytial virusRespiratory Syncytial Virus VaccinesVaccines, AttenuatedViral ProteinsViroporin Proteinshuman respiratory syncytial virusimmune efficacylive-attenuated vaccineM2-2 geneSubgroup A strain Long

Identifiers

PMID42338594
PMCPMC13283998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.